Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 5NETWORK 4INDUSTRY 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 1Invasive Pulmonary Aspergillosis 1Hematologic Neoplasms 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Caspofungin × Clear all
NCT02895529 2019-05-06

A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy

Xian-Janssen Pharmaceutical Ltd.

Phase 4 Terminated
61 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT02856178 2018-02-15

SAFEGUARD

F2G Biotech GmbH

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Invasive Pulmonary Aspergillosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡